Form 8K May 8 2013


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported) – May 7, 2013
 
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

 
 
 
 
 
Pennsylvania
 
1-8036
 
23-1210010
(State or other jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
530 Herman O. West Drive, Exton, PA
 
 
 
19341-0645
(Address of principal executive offices)
 
 
 
(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 






Item 5.07  Submission of Matters to a Vote of Security Holders.

Our 2013 Annual Meeting of Shareholders was held on May 7, 2013 at the Company's corporate headquarters. Our shareholders voted on three proposals at the Annual Meeting. The proposals are described in detail in our definitive proxy statement dated March 27, 2013. As of March 11, 2013, the record date, there were 34,612,051 shares outstanding. Shareholders representing 31,820,664 or 91.93%, of the common shares outstanding were present in person or were represented by proxy. The final results for the votes on each proposal are set forth below.

Proposal 1: Our shareholders elected the following directors to serve on our Board until the 2014 Annual Meeting of Shareholders.

Name
For
Withheld
Broker Non-Votes
Mark A. Buthman
29,836,060
33,623

1,950,981

William F. Feehery
29,841,746
27,937

1,950,981

Thomas W. Hofmann
29,832,267
37,416

1,950,981

L. Robert Johnson
29,797,357
72,326

1,950,981

Paula A. Johnson
29,844,971
24,712

1,950,981

Douglas A. Michels
29,841,646
28,037

1,950,981

Donald E. Morel, Jr.
29,095,547
774,136

1,950,981

John H. Weiland
29,357,584
512,099

1,950,981

Anthony Welters
28,718,098
1,151,585

1,950,981

Patrick J. Zenner
29,351,922
517,761

1,950,981


Proposal 2: Our shareholders approved, on an advisory basis, named executive officer compensation:
 
For
Against
Abstain
Broker Non-Votes
28,230,633
1,627,279
11,771
1,950,981

Proposal 3: Our shareholders ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2013 fiscal year. The votes regarding this proposal were as follows:
 
For
Against
Abstain
Broker Non-Votes
31,110,283
703,531
6,850
Not applicable







SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
 
 
 
/s/ John R. Gailey III
 
 
John R. Gailey III, Senior Vice President,
 
 
General Counsel and Secretary
 
 
 
 
 
 
 
May 8, 2013